Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hui Luo(Sun Yat-sen University), Guangqiang Zhao, Jianjun Zou(Jiangsu Hengrui Medicine (China)), Yu Shen(University of Florida), Yong Gao(Shanghai East Hospital), Helong Zhang(Shanghai International Studies University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Bing Xia, Junyan Yu(Changzhi Medical College), Sanyuan Sun, Shegan Gao(Henan University of Science and Technology), Zuoxing Niu(Shandong Tumor Hospital), Jun Wang(Hebei Medical University), Ying Cheng(Jilin Province Tumor Hospital), Kuaile Zhao(Shanghai Medical College of Fudan University), Jun Bie, Suxia Luo(Zhengzhou University), Lin Wu(Materials Systems (United States)), Yuxian Bai(Harbin Medical University), Xiaodong Zhang(The University of Texas MD Anderson Cancer Center), Li Chen(Novartis (United States)), Dong Wang(Zhejiang Chinese Medical University), Ying Liu(Chongqing University), Li Zhang(Fourth Hospital of Changsha), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Tianshu Liu(Sun Yat-sen University), Dong Ma, Ji‐Feng Feng(Jiangsu Cancer Hospital), Wei Ren, Zhendong Chen(Anhui Medical University), Kangsheng Gu(Anhui Medical University), Yiping Zhang(Henan Normal University), Jiancheng Li(Fujian Medical University), Jin Lü(Sichuan Cancer Hospital), Xiuwen Wang(Second Hospital of Shandong University), Qingxia Fan(First Affiliated Hospital of Zhengzhou University), Rui‐Hua Xu(Sun Yat-sen University), Xianglin Yuan(Tongji Hospital), Zhichao Fu(South China Agricultural University), Xuhong Min(Xi'an Chest Hospital), Yifu He(Anhui Provincial Hospital), Likun Liu, Teng Mao(Bristol-Myers Squibb (Germany)), Fengming Ran, Zhanhui Miao, Feng Ye, Emily Liu(University of Iowa), Zhihua Liu(California Institute of Technology), Qing Yang(Guangzhou University of Chinese Medicine)
Cited by 821
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k